These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21807788)

  • 21. Validating Rheumatoid Arthritis Remission Using the Patients' Perspective: Results from a Special Interest Group at OMERACT 2016.
    Rasch LA; Boers M; Hill CL; Voshaar M; Hoogland W; de Wit M; Flurey C; Davis B; Hetland ML; Brahe CH; Gossec L; Wells GA; Tugwell P; Kuriya B; Goel N; Singh JA; Duarte C; Da Silva J; van Schaardenburg D; Proudman S; van Tuyl LHD;
    J Rheumatol; 2017 Dec; 44(12):1889-1893. PubMed ID: 28765250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Developing a construct to evaluate flares in rheumatoid arthritis: a conceptual report of the OMERACT RA Flare Definition Working Group.
    Alten R; Pohl C; Choy EH; Christensen R; Furst DE; Hewlett SE; Leong A; May JE; Sanderson TC; Strand V; Woodworth TG; Bingham CO;
    J Rheumatol; 2011 Aug; 38(8):1745-50. PubMed ID: 21807796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective: The OMERACT glucocorticoid core domain set.
    Tieu J; Cheah JT; Black RJ; Christensen R; Ghosh N; Richards P; Robson J; Shea B; Simon LS; Singhi JA; Tugwell P; Boers M; Garibay MAA; Campochiaro C; Decary S; de Witt M; Fernandez AP; Keen HI; King L; Hinojosa-Azaola A; Hofstetter C; Gaydukova I; George MD; Gupta L; Lyne S; Makol A; Mukhtyar C; Oo WM; Petri M; Pisaniello HL; Sattui SE; Russell O; Teixeira V; Toupin-April K; Uhunmwangho C; Whitstock M; Yip K; Mackie SL; Goodman SM; Hill CL
    Semin Arthritis Rheum; 2021 Oct; 51(5):1139-1145. PubMed ID: 34253398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Minimal clinically important difference, low disease activity state, and patient acceptable symptom state: methodological issues.
    Tubach F; Wells GA; Ravaud P; Dougados M
    J Rheumatol; 2005 Oct; 32(10):2025-9. PubMed ID: 16206363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient-reported outcomes in rheumatoid arthritis.
    Her M; Kavanaugh A
    Curr Opin Rheumatol; 2012 May; 24(3):327-34. PubMed ID: 22410543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Critical Outcomes in Longitudinal Observational Studies and Registries in Patients with Rheumatoid Arthritis: An OMERACT Special Interest Group Report.
    Zamora NV; Christensen R; Goel N; Klokker L; Lopez-Olivo MA; Kristensen LE; Carmona L; Strand V; Curtis JR; Suarez-Almazor ME
    J Rheumatol; 2017 Dec; 44(12):1894-1898. PubMed ID: 28620065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identifying preliminary domains to detect and measure rheumatoid arthritis flares: report of the OMERACT 10 RA Flare Workshop.
    Bingham CO; Alten R; Bartlett SJ; Bykerk VP; Brooks PM; Choy E; Christensen R; Furst DE; Hewlett SE; Leong A; May JE; Montie P; Pohl C; Sanderson TC; Strand V; Woodworth TG;
    J Rheumatol; 2011 Aug; 38(8):1751-8. PubMed ID: 21807797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes from the Patient Perspective Workshop at OMERACT 6.
    Kirwan J; Heiberg T; Hewlett S; Hughes R; Kvien T; Ahlmèn M; Boers M; Minnock P; Saag K; Shea B; Suarez Almazor M; Taal E
    J Rheumatol; 2003 Apr; 30(4):868-72. PubMed ID: 12672218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced Patient Involvement and the Need to Revise the Core Set - Report from the Psoriatic Arthritis Working Group at OMERACT 2014.
    Tillett W; Eder L; Goel N; De Wit M; Gladman DD; FitzGerald O; Campbell W; Helliwell PS; Gossec L; Orbai AM; Ogdie A; Strand V; McHugh NJ; Mease PJ
    J Rheumatol; 2015 Nov; 42(11):2198-203. PubMed ID: 25934828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome Domains and Measures in Total Joint Replacement Clinical Trials: Can We Harmonize Them? An OMERACT Collaborative Initiative.
    Singh JA; Dohm M; Sprowson AP; Wall PD; Richards BL; Gossec L; Hawker GA; Riddle DL; Buchbinder R
    J Rheumatol; 2015 Dec; 42(12):2496-502. PubMed ID: 25834208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What has been the effect on trial outcome assessments of a decade of patient participation in OMERACT?
    de Wit MP; Abma TA; Koelewijn-van Loon MS; Collins S; Kirwan J
    J Rheumatol; 2014 Jan; 41(1):177-84. PubMed ID: 24128777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient perspective in outcome assessments--perceptions or something more?
    Kvien TK; Heiberg T
    J Rheumatol; 2003 Apr; 30(4):873-6. PubMed ID: 12672219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The OMERACT Stepwise Approach to Select and Develop Imaging Outcome Measurement Instruments: The Musculoskeletal Ultrasound Example.
    Terslev L; Naredo E; Keen HI; Bruyn GAW; Iagnocco A; Wakefield RJ; Conaghan PG; Maxwell LJ; Beaton DE; Boers M; D'Agostino MA
    J Rheumatol; 2019 Oct; 46(10):1394-1400. PubMed ID: 30877208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The evolution of instrument selection for inclusion in core outcome sets at OMERACT: Filter 2.2.
    Maxwell LJ; Beaton DE; Boers M; D'Agostino MA; Conaghan PG; Grosskleg S; Shea BJ; Bingham Iii CO; Boonen A; Christensen R; Choy E; Doria AS; Hill CL; Hofstetter C; Kroon FP; Leung YY; Mackie S; Meara A; Touma Z; Tugwell P; Wells GA
    Semin Arthritis Rheum; 2021 Dec; 51(6):1320-1330. PubMed ID: 34544617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting.
    Holland R; Tillett W; Ogdie A; Leung YY; Gladman DD; Callis Duffin K; Coates LC; Mease PJ; Eder L; Strand V; Elmamoun M; Højgaard P; Chau J; de Wit M; Goel N; Lindsay CA; FitzGerald O; Shea B; Beaton D; Orbai AM
    J Rheumatol Suppl; 2018 Jun; 94():17-25. PubMed ID: 29858348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A method for achieving consensus on rheumatoid arthritis outcome measures: the OMERACT conference process.
    Fried BJ; Boers M; Baker PR
    J Rheumatol; 1993 Mar; 20(3):548-51. PubMed ID: 8478870
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The OMERACT First-time Participant Program: Fresh Eye from the New Guys.
    Sloan VS; Grosskleg S; Pohl C; Wells GA; Singh JA
    J Rheumatol; 2017 Oct; 44(10):1560-1563. PubMed ID: 28507185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology.
    Maxwell LJ; Beaton DE; Shea BJ; Wells GA; Boers M; Grosskleg S; Bingham CO; Conaghan PG; D'Agostino MA; de Wit M; Gossec L; March L; Simon LS; Singh JA; Strand V; Tugwell P
    J Rheumatol; 2019 Aug; 46(8):1014-1020. PubMed ID: 30770502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incorporating the patient's perspective in outcomes research.
    Hsiao B; Fraenkel L
    Curr Opin Rheumatol; 2017 Mar; 29(2):144-149. PubMed ID: 28072590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MRI of rheumatoid arthritis:comparing the outcome measures in rheumatology clinical trials (OMERACT) scoring and volume of synovitis for the assessment of biologic therapy.
    Nakahara R; Nishida K; Hashizume K; Harada R; Machida T; Horita M; Ohtsuka A; Ozaki T
    Acta Med Okayama; 2015; 69(1):29-35. PubMed ID: 25703168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.